These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18992790)

  • 1. Iron overload following red blood cell transfusion and its impact on disease severity.
    Ozment CP; Turi JL
    Biochim Biophys Acta; 2009 Jul; 1790(7):694-701. PubMed ID: 18992790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
    Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does non-transferrin bound iron contribute to transfusion related immune-modulation in preterms?
    Stark MJ; Keir AK; Andersen CC
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F424-9. PubMed ID: 23475935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron and oxidative stress in cardiomyopathy in thalassemia.
    Berdoukas V; Coates TD; Cabantchik ZI
    Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
    Shander A; Cappellini MD; Goodnough LT
    Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences and management of iron overload in sickle cell disease.
    Porter J; Garbowski M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of transfusional iron overload.
    Porter JB; Garbowski M
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):683-701, vi. PubMed ID: 25064708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
    Wang WC; Ahmed N; Hanna M
    J Pediatr; 1986 Apr; 108(4):552-7. PubMed ID: 3083076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and management of iron toxicity in thalassemia.
    Hershko C
    Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A; Sazama K
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia.
    Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE
    Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies in the treatment of the thalassemias.
    Schrier SL; Angelucci E
    Annu Rev Med; 2005; 56():157-71. PubMed ID: 15660507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation.
    Hod EA; Zhang N; Sokol SA; Wojczyk BS; Francis RO; Ansaldi D; Francis KP; Della-Latta P; Whittier S; Sheth S; Hendrickson JE; Zimring JC; Brittenham GM; Spitalnik SL
    Blood; 2010 May; 115(21):4284-92. PubMed ID: 20299509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.